GW’s Epidiolex Approval Encouraging For Pharma-grade Cannabinoid Pipeline


Executive Summary

Beyond Epidiolex for severe epilepsy, cannabinoid candidates are in development for a range of diseases, including acute pain, graft-versus-host disease, scleroderma, schizophrenia, pain and substance use disorder.

...read more at https://scrip.pharmaintelligence.informa.com/SC123341/GWs-Epidiolex-Approval-Encouraging-For-Pharmagrade-Cannabinoid-Pipeline